Maia Biotechnology Doses First Patients in Europe in Ongoing Phase II Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

The primary objectives of the THIO-101 trial were to evaluate the safety and tolerability, as well as preliminary clinical efficacy of THIO, a first-in-class cancer telomere targeting agent, in patients with advanced NSCLC, who either progressed or relapsed through the initial treatments with an immune checkpoint inhibitor alone, or in combination with chemotherapy.